Key clinical point: Apremilast significantly improved nail-specific quality of life, clinical signs, and ultrasound parameters, along with a consistent safety profile in patients with psoriasis and predominant nail disease.
Major finding: At 52 weeks, 52% of patients had Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) Patient Benefit Index global weighted score of 2 or more. Median NAPPA Quality of Life and fingernail Nail Psoriasis Severity Index (NAPSI) improved by 57% and 53%, respectively. Ultrasound parameters improved from 16 weeks onward. Adverse events were mostly mild and transient.
Study details: This was a prospective cohort study that included 45 adult patients with plaque and nail psoriasis and a fingernail NAPSI score of 12 or more who were treated with apremilast 30 mg twice a day for 52 weeks.
Disclosures: This study was supported by Amgen. Dr. Muñoz-Santos, Dr. Vidal, and Dr. Guilabert declared receiving personal fees, presentation honoraria, or travel expenses from various sources including Amgen.
Source: Muñoz-Santos C et al. J Dermatol. 2021 Aug 12. doi: 10.1111/1346-8138.16074 .